Strategic partnerships CureLab Oncology is actively advancing Phase II trials and expanding presence outside the US, presenting an opportunity to engage potential CROs, global clinical trial networks, and regional distributors for trial management, regulatory support, and manufacturing partnerships.

Clinical evidence Lead product Elenagen™ has demonstrated safety and clinical benefits across Phase I/IIa, with ongoing Phase II trials including plans in the US, creating a compelling case for academic and hospital collaborations, investigator-initiated studies, and patient referral programs.

Expanded portfolio Diversification efforts include veterinary applications through CureLab Veterinary, signaling potential cross-selling of platform technologies to veterinary oncology partners and distributors, as well as potential licensing opportunities for companion animal markets.

Key leadership New chief medical officer appointed in 2024, plus leadership with significant EU healthcare experience, enabling strategic discussions with multinational pharma companies, contract research organizations, and regulatory consultants for co-development and licensing deals.

Market fit Targeting oncology indications such as platinum-resistant ovarian cancer and immuno-oncology combinations, with a platform capable of enhancing other therapies, offering sales dialogue for collaboration with chemotherapy, immunotherapy, and inflammation management partners seeking synergistic therapies.